新型三氨基嘧啶ZY-19489的安全性、药代动力学和抗疟活性:首次人体、随机、安慰剂对照、双盲、单次递增剂量研究、初步食物效应研究和志愿者感染研究
在澳大利亚布里斯班健康成人中开展三部分临床试验:单次递增剂量组(25–1500 mg)中1500 mg组药物相关不良事件发生率高于低剂量组和安慰剂组,主要为轻度胃肠道症状;食物效应研究显示进食延迟吸收但不影响总暴露;志愿者感染研究中所有受试者均出现快速初始寄生虫清除,200 mg和300 mg组多数出现复燃,900 mg组2例均无复燃;药效学模型模拟预测单次1100 mg可使基线寄生虫血症降低10^9倍。
要点
- 1500 mg组6/6发生药物相关不良事件,低剂量组和安慰剂组发生率较低,主要为轻度胃肠道症状。
- 进食状态延迟达峰时间(中位12.0 h vs 6.0 h),但总暴露无差异(AUC差值-0.013,90%CI -0.11至0.08)。
- 志愿者感染研究中清除半衰期6.6–7.1 h,200 mg组4/5和300 mg组5/8复燃,900 mg组0/2复燃。
核心结论
- ZY-19489在人体中的安全性、药代动力学特征和抗疟活性支持该化合物作为新型抗疟疗法的进一步开发。
研究设计与样本
- 三部分临床试验在澳大利亚昆士兰州布里斯班的健康成人(18–55岁)中开展。
- 第一部分为双盲、随机、安慰剂对照、单次递增剂量研究,参与者入组六个剂量组(25、75、150、450、900或1500 mg),按3:1随机分配至ZY-19489或安慰剂。
- 第二部分为开放标签、随机、两周期交叉、初步食物效应研究,按1:1随机分配至空腹-进食或进食-空腹序列。
- 第三部分为开放标签、随机、志愿者感染研究,采用恶性疟原虫诱导血阶段疟疾模型,入组两个队列,队列一所有参与者接受相同剂量ZY-19489,队列二随机接受两种剂量之一。
主要发现
- 第一部分48名参与者入组(25–1500 mg各队列8名),药物相关不良事件发生率在1500 mg组为6/6,25 mg组1/6、75 mg组2/6、150 mg组3/6、450 mg组2/6、900 mg组4/6、安慰剂组4/12。
- 第一部分最大血浆浓度出现在给药后5–9 h,消除半衰期在剂量范围内为50–97 h。
- 第二部分8名参与者入组(每组4名,均给药300 mg),进食状态3/7发生治疗相关不良事件,空腹状态4/8发生。
- 第二部分进食状态达峰时间中位12.0 h(范围7.5–16.0)vs 空腹状态6.0 h(4.5–9.1),从0时间(给药)外推至无穷大的浓度-时间曲线下面积进食与空腹状态差值为-0.013(90%CI -0.11至0.08)。
- 第三部分15名参与者入组(200 mg组5名、300 mg组8名、900 mg组2名),药物相关不良事件200 mg组4/5、300 mg组7/8、900 mg组2/2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New antimalarials with novel mechanisms of action are needed to combat the emergence of drug resistance. Triaminopyrimidines comprise a novel antimalarial class identified in a high-throughput screen against asexual blood-stage Plasmodium falciparum. This first-in-human study aimed to characterise the safety, pharmacokinetics, and antimalarial activity of the triaminopyrimidine ZY-19489 in healthy volunteers. METHODS: A three-part clinical trial was conducted in healthy adults (aged 18-55 years) in Brisbane, QLD, Australia. Part one was a double-blind, randomised, placebo-controlled, single ascending dose study in which participants enrolled into one of six dose groups (25, 75, 150, 450, 900, or 1500 mg) were randomly assigned (3:1) to ZY-19489 or placebo. Part two was an open-label, randomised, two-period cross-over, pilot food-effect study in which participants were randomly assigned (1:1) to a fasted-fed or a fed-fasted sequence. Part three was an open-label, randomised, volunteer infection study using the P falciparum induced blood-stage malaria model in which participants were enrolled into one of two cohorts, with participants in cohort one all receiving the same dose of ZY-19489 and participants in cohort two randomly assigned to receive one of two doses. The primary outcome for all three parts was the incidence, severity, and relationship to ZY-19489 of adverse events. Secondary outcomes were estimation of ZY-19489 pharmacokinetic parameters for all parts; how these parameters were affected by the fed state for part two only; and the parasite reduction ratio, parasite clearance half-life, recrudescent parasitaemia, and pharmacokinetic-pharmacodynamic modelling parameters for part three only. This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12619000127101, ACTRN12619001466134, and ACTRN12619001215112). FINDINGS: 48 participants were enrolled in part one (eight per cohort for 25-1500 mg cohorts), eight in part two (four in each group, all dosed with 300 mg), and 15 in part three (five dosed with 200 mg, eight with 300 mg, and two with 900 mg). In part one, the incidence of drug-related adverse events was higher in the 1500 mg dose group (occurring in all six participants) than in lower-dose groups and the placebo group (occurring in one of six in the 25 mg group, two of six in the 75 mg group, three of six in the 150 mg group, two of six in the 450 mg group, four of six in the 900 mg group, and four of 12 in the placebo group), due to the occurrence of mild gastrointestinal symptoms. Maximum plasma concentrations occurred 5-9 h post-dosing, and the elimination half-life was 50-97 h across the dose range. In part two, three of seven participants had a treatment-related adverse event in the fed state and four of eight in the fasted state. Dosing in the fed state delayed absorption (maximum plasma concentration occurred a median of 12·0 h [range 7·5-16·0] after dosing in the fed state vs 6·0 h [4·5-9·1] in the fasted state) but had no effect on overall exposure (difference in area under the concentration-time curve from time 0 [dosing] extrapolated to infinity between fed and fasted states was -0·013 [90% CI -0·11 to 0·08]). In part three, drug-related adverse events occurred in four of five participants in the 200 mg group, seven of eight in the 300 mg group, and both participants in the 900 mg group. Rapid initial parasite clearance occurred in all participants following dosing (clearance half-life 6·6 h [95% CI 6·2-6·9] for 200 mg, 6·8 h [95% CI 6·5-7·1] for 300 mg, and 7·1 h [95% CI 6·6-7·6] for 900 mg). Recrudescence occurred in four of five participants in the 200 mg group, five of eight in the 300 mg group, and neither of the two participants in the 900 mg group. Simulations done using a pharmacokinetic-pharmacodynamic model predicted that a single dose of 1100 mg would clear baseline parasitaemia by a factor of 109. INTERPRETATION: The safety, pharmacokinetic profile, and antimalarial activity of ZY-19489 in humans support the further development of the compound as a novel antimalarial therapy. FUNDING: Cadila Healthcare and Medicines for Malaria Venture.
引用
- Barber BE, Fernandez M, Patel HB, et al. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. Lancet Infect Dis. 2022. PMID: 35247321. doi:10.1016/S1473-3099(21)00679-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。